Trung Huynh
Stock Analyst at RBC Capital
(4.56)
# 208
Out of 5,182 analysts
64
Total ratings
64.44%
Success rate
20.34%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trung Huynh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Reiterates: Underperform | $25 | $25.68 | -2.65% | 8 | Apr 20, 2026 | |
| MRK Merck & Co. | Reiterates: Outperform | $142 | $111.38 | +27.49% | 6 | Mar 30, 2026 | |
| LLY Eli Lilly and Company | Initiates: Outperform | $1,250 | $948.45 | +31.79% | 11 | Feb 25, 2026 | |
| BMY Bristol-Myers Squibb Company | Initiates: Sector Perform | $60 | $56.16 | +6.84% | 6 | Feb 25, 2026 | |
| ABBV AbbVie | Initiates: Outperform | $260 | $201.55 | +29.00% | 2 | Feb 25, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $595 → $660 | $714.89 | -7.68% | 5 | Nov 7, 2025 | |
| INSM Insmed | Maintains: Buy | $194 → $223 | $101.35 | +120.03% | 9 | Oct 31, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $29 → $25 | $0.93 | +2,598.91% | 3 | Aug 15, 2025 | |
| AMGN Amgen | Maintains: Neutral | $326 → $317 | $331.70 | -4.43% | 6 | Aug 6, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $44 → $38 | $33.97 | +11.86% | 2 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $7 | $3.88 | +80.41% | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $9.35 | +39.04% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $170 → $175 | $221.32 | -20.93% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $8.08 | - | 1 | Mar 23, 2021 |
Pfizer
Apr 20, 2026
Reiterates: Underperform
Price Target: $25
Current: $25.68
Upside: -2.65%
Merck & Co.
Mar 30, 2026
Reiterates: Outperform
Price Target: $142
Current: $111.38
Upside: +27.49%
Eli Lilly and Company
Feb 25, 2026
Initiates: Outperform
Price Target: $1,250
Current: $948.45
Upside: +31.79%
Bristol-Myers Squibb Company
Feb 25, 2026
Initiates: Sector Perform
Price Target: $60
Current: $56.16
Upside: +6.84%
AbbVie
Feb 25, 2026
Initiates: Outperform
Price Target: $260
Current: $201.55
Upside: +29.00%
Regeneron Pharmaceuticals
Nov 7, 2025
Maintains: Neutral
Price Target: $595 → $660
Current: $714.89
Upside: -7.68%
Insmed
Oct 31, 2025
Maintains: Buy
Price Target: $194 → $223
Current: $101.35
Upside: +120.03%
Jasper Therapeutics
Aug 15, 2025
Maintains: Buy
Price Target: $29 → $25
Current: $0.93
Upside: +2,598.91%
Amgen
Aug 6, 2025
Maintains: Neutral
Price Target: $326 → $317
Current: $331.70
Upside: -4.43%
Celldex Therapeutics
May 9, 2025
Maintains: Buy
Price Target: $44 → $38
Current: $33.97
Upside: +11.86%
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $3.88
Upside: +80.41%
Oct 10, 2024
Initiates: Buy
Price Target: $13
Current: $9.35
Upside: +39.04%
Jul 21, 2023
Maintains: Neutral
Price Target: $170 → $175
Current: $221.32
Upside: -20.93%
Mar 23, 2021
Upgrades: Outperform
Price Target: n/a
Current: $8.08
Upside: -